Autopsy report · NCT01478360
Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled Asthma
Cause of deathOther
“Further investigations would require changes in study design; the use of different endpoints, a different IL-17 antibody or a different patient population.”
Life of this trial
- Registered 4 months before it started.
- Ran for about 2 years 8 months before it stopped.
- 46 participants enrolled.
- Results were posted on the registry 1 year after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Asthma
- Interventions
- AIN457 (secukinumab); Placebo
- Participants
- 46
- Sites
- 9
- Countries
- Germany, United Kingdom
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.